Siga Technologies (SIGA) Net Income towards Common Stockholders (2010 - 2025)
Siga Technologies (SIGA) reported Net Income towards Common Stockholders of -$6.4 million for Q3 2025, down 573.67% on a YoY basis from $1.3 million in Q3 2024, and down 117.95% quarter-over-quarter from $35.5 million in Q2 2025.
Siga Technologies (SIGA) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Siga Technologies has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$6.4 million in Q3 2025.
- For the quarter ending Q3 2025, Net Income towards Common Stockholders fell 573.67% year-over-year to -$6.4 million; the trailing twelve-month figure through Dec 2025 stood at $28.7 million (down 51.48% YoY), and the FY2024 full-year result was $59.2 million, down 13.01% from the prior year.
- Net Income towards Common Stockholders for Q3 2025 stood at -$6.4 million, down from $35.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $73.4 million in Q4 2021, with the low at -$6.4 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged $13.6 million across 5 years, with a median of -$258928.0 in 2021.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 9000.73% — and 2025, when it sank 573.67%.
- Siga Technologies' Net Income towards Common Stockholders stood at $73.4 million in 2021, then tumbled by 101.11% to -$811794.0 in 2022, then surged by 9000.73% to $72.3 million in 2023, then sank by 36.67% to $45.8 million in 2024, then sank by 113.91% to -$6.4 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$6.4 million (Q3 2025), $35.5 million (Q2 2025), and -$370415.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Siga Technologies | 310.79 Mn | 155.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | 35.47 Mn |
| Mar 31, 2025 | -370,415.00 |
| Dec 31, 2024 | 45.76 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 10.32 Mn |
| Dec 31, 2023 | 72.26 Mn |
| Sep 30, 2023 | -393,066.00 |
| Jun 30, 2023 | -2.88 Mn |
| Mar 31, 2023 | -918,255.00 |
| Dec 31, 2022 | -811,794.00 |
| Sep 30, 2022 | 33.04 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -364,455.00 |
| Dec 31, 2021 | 73.38 Mn |
| Sep 30, 2021 | -3.11 Mn |
| Jun 30, 2021 | -258,928.00 |
| Mar 31, 2021 | -1.73 Mn |
| Dec 31, 2020 | 20.16 Mn |